DA
ABBV icon

DCF Advisers’s AbbVie ABBV Stock Holding History

DCF Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.71M Hold
10,750
– – 0.48% 37
2026
Q1 		$2.34M Hold
10,750
– – 0.62% 38
2025
Q4 		$2.46M Hold
10,750
– – 0.66% 43
2025
Q3 		$2.49M Hold
10,750
– – 0.8% 37
2025
Q2 		$2M Hold
10,750
– – 0.92% 38
2025
Q1 		$2.25M Sell
10,750
-20,750
-66% -$4.03M 1.08% 32
2024
Q4 		$5.6M Buy
31,500
+500
+2% +$91.9K 2.71% 10
2024
Q3 		$6.12M Sell
31,000
-800
-3% -$149K 2.45% 10
2024
Q2 		$5.45M Hold
31,800
– – 2.81% 8
2024
Q1 		$5.79M Sell
31,800
-700
-2% -$121K 2.85% 9
2023
Q4 		$5.04M Sell
32,500
-12,000
-27% -$1.75M 2.73% 9
2023
Q3 		$6.63M Sell
44,500
-3,050
-6% -$448K 3.61% 6
2023
Q2 		$6.41M Sell
47,550
-24,450
-34% -$3.59M 3.38% 7
2023
Q1 		$11.5M Hold
72,000
– – 7.02% 2
2022
Q4 		$11.6M Sell
72,000
-4,100
-5% -$629K 7.86% 2
2022
Q3 		$10.2M Buy
76,100
+1,000
+1% +$143K 6.6% 1
2022
Q2 		$11.5M Sell
75,100
-13,650
-15% -$2.09M 6.85% 2
2022
Q1 		$14.4M Sell
88,750
-10,568
-11% -$1.54M 6.3% 3
2021
Q4 		$13.4M Buy
99,318
+21,568
+28% +$2.55M 5.45% 5
2021
Q3 		$8.39M Buy
77,750
+750
+1% +$85.7K 3.7% 6
2021
Q2 		$8.67M Sell
77,000
-25,000
-25% -$2.82M 3.07% 5
2021
Q1 		$11M Buy
102,000
+21,000
+26% +$2.25M 4.8% 4
2020
Q4 		$8.68M Buy
81,000
+17,000
+27% +$1.63M 3.58% 8
2020
Q3 		$5.61M Buy
64,000
+4,850
+8% +$457K 2.87% 10
2020
Q2 		$5.81M Sell
59,150
-6,000
-9% -$528K 3.25% 10
2020
Q1 		$4.96M Buy
65,150
+6,550
+11% +$558K 3.25% 7
2019
Q4 		$5.19M Buy
+58,600
New +$4.86M 3.29% 9

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCF Advisers's ABBV Position: Q2 2026 in Review

DCF Advisers held its AbbVie (ABBV) position steady in Q2 2026 at 10,750 shares worth $2.71M. The position accounts for 0.48% of the portfolio, ranked #37.

DCF Advisers first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $14.4M in Q1 2022. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • DCF Advisers held 10,750 shares of AbbVie worth $2.71M as of Q2 2026.
  • DCF Advisers left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.48% of DCF Advisers's portfolio in Q2 2026, its #37 holding.
  • DCF Advisers first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • DCF Advisers's AbbVie position peaked at $14.4M in Q1 2022.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.